Active	Status	Sponsor type	Region	Phase	Filter
10 Active 1 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fokkens, Wytske J
NCT04670172: Real-Life Chronic Rhinosinusitis Outcome Registry	Recruiting	N/A	4550	Europe		Change Accelerator in Respiratory Care	Chronic Rhinosinusitis (Diagnosis)	06/24	12/24
Reitsma, Sietze
ANCHOR-1, NCT05274750 / 2021-005037-16: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps Jul 2024 - Dec 2024 : Acceptance of regulatory submission in US for CRSwNP	Completed	3	276	Europe, Canada, Japan, US, RoW	Depemokimab (GSK3511294), Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Nasal Polyps	07/24	08/24
NCT04670172: Real-Life Chronic Rhinosinusitis Outcome Registry	Recruiting	N/A	4550	Europe		Change Accelerator in Respiratory Care	Chronic Rhinosinusitis (Diagnosis)	06/24	12/24
NCT03704415: Aggravated Airway Inflammation: Research on Genomics and Optimal Operative Treatment (AirGOs Operative)	Active, not recruiting	N/A	97	Europe	Extended endoscopic sinus surgery, Limited endoscopic sinus surgery	Helsinki University Central Hospital	Sinusitis, Chronic, Asthma, Nasal Polyps, Aspirin Sensitivity	12/24	12/24
Gevaert, Philippe
NCT04898764: Research on Underlying Causes of Long-term Use of Nasal Decongestants and the Structured Withdrawal of the Decongestant	Recruiting	4	135	Europe	Mometasone Furoate	University Hospital, Ghent	Rhinitis Medicamentosa	12/25	12/25
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)	Recruiting	3	510	Europe, Canada, Japan, US, RoW	LY3650150, Placebo, Standard therapy for INCS	Eli Lilly and Company	Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	10/26	02/27
ANCHOR-1, NCT05274750 / 2021-005037-16: Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps Jul 2024 - Dec 2024 : Acceptance of regulatory submission in US for CRSwNP	Completed	3	276	Europe, Canada, Japan, US, RoW	Depemokimab (GSK3511294), Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Nasal Polyps	07/24	08/24
NCT04670172: Real-Life Chronic Rhinosinusitis Outcome Registry	Recruiting	N/A	4550	Europe		Change Accelerator in Respiratory Care	Chronic Rhinosinusitis (Diagnosis)	06/24	12/24
NASUMAB, NCT05938972: Real Life Study of Biologicals in Patients With Severe CRSwNP	Recruiting	N/A	180	Europe	Mepolizumab, Omalizumab, Dupilumab	University Hospital, Ghent	Chronic Rhinosinusitis With Nasal Polyps	12/30	12/30
Cornet, Marjolein
NCT04670172: Real-Life Chronic Rhinosinusitis Outcome Registry	Recruiting	N/A	4550	Europe		Change Accelerator in Respiratory Care	Chronic Rhinosinusitis (Diagnosis)	06/24	12/24